The Role of Age in Subclinical Atherosclerosis in Asian People Living with Human Immunodeficiency Virus

Sunghee Park 1, Se Yoon Park 2,3, Eunjung Lee 4, Tae Hyong Kim 4, and Eunyoung Lee 5

1Division of Infectious Diseases, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
2Department of Hospital Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
3Centers for Digital Health, Yongin Severance Hospital, Yonsei University Health System, Yongin, Korea
4Division of Infectious Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
5Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea

ABSTRACT

Background: People living with human immunodeficiency virus (PLHIV) have an increased risk of atherosclerosis and cardiovascular disease, but specific guidance on when to suspect the onset of these diseases is limited.

Materials and Methods: We aimed to identify cardiovascular risk factors in PLHIV using carotid intima-media thickness (IMT) through a cross-sectional, retrospective cohort study that enrolled 217 PLHIV who underwent carotid IMT measurement at a teaching hospital in Korea. We compared clinical characteristics between PLHIV with subclinical atherosclerosis and PLHIV with IMT within the normal range, and used a receiver operating characteristic curve to determine the cut-off age for predicting subclinical atherosclerosis.

Results: Among the study population, 115 participants (53.0%) had subclinical atherosclerosis. In logistic regression, age and dyslipidemia were significantly associated with increased carotid IMT even after adjusting for other variables (odds ratio [OR]: 1.11, 95% confidence interval [CI]: 1.06 - 1.15, P <0.001; OR: 3.92, 95% CI: 1.87 - 8.22, P <0.001, respectively). The cut-off age for predicting subclinical atherosclerosis was 39.5 years (area under the curve 0.78, 95% CI: 0.72 - 0.84, P <0.001).

Conclusion: Conventional risk factors including age and dyslipidemia were associated with subclinical atherosclerosis. In logistic regression, age and dyslipidemia were significantly associated with increased carotid IMT even after adjusting for other variables (odds ratio [OR]: 1.11, 95% confidence interval [CI]: 1.06 - 1.15, P <0.001; OR: 3.92, 95% CI: 1.87 - 8.22, P <0.001, respectively). The cut-off age for predicting subclinical atherosclerosis was 39.5 years (area under the curve 0.78, 95% CI: 0.72 - 0.84, P <0.001).

Keywords: HIV; Carotid intima-media thickness; Risk factors; Dyslipidemia; Cardiovascular disease

INTRODUCTION

Effective antiretroviral therapy (ART) provides longer life expectancy for people living with human immunodeficiency virus (PLHIV), and thus, the prevention and control of chronic comorbidities including cardiovascular disease (CVD) have become an important part of HIV management.
PLHIV are at an increased risk of developing atherosclerosis and CVD, and have a higher risk of mortality [1-3]. While traditional risk factors such as smoking and obesity may coexist, HIV itself is an independent risk factor for CVD among PLHIV [4, 5]. Acquired immunodeficiency syndrome (AIDS) was also reported to be associated with atherosclerosis and CVD [6, 7].

Carotid intima-media thickness (IMT) is frequently used in Korea as a surrogate marker of atherosclerosis and CVD due to its noninvasive, sensitive, and reproducible properties [8, 9]. Several studies have examined the association between carotid IMT and HIV infection, but the results have been largely inconclusive. While a couple of studies have reported increased carotid IMT in PLHIV [10, 11], other studies show an increase in carotid IMT only in certain subgroups, such as those taking protease inhibitors [12, 13].

Although Asia has a significant HIV burden with growing health issues concerning CVD, little is known about CVD in Asian PLHIV [14]. Since the prevalence of atherosclerosis varies according to ethnicity and region, building local epidemiologic data is a key step to updating guidelines [15]. Furthermore, as ART has become the generalized treatment for HIV/AIDS, cumulative data regarding atherosclerosis are needed on PLHIV who have received long-term ART. In this study, we aimed to compare the clinical characteristics of PLHIV in Korea according to their carotid IMT values and clarify the risk factors for subclinical atherosclerosis in PLHIV.

**MATERIALS AND METHODS**

1. **Study population and design**
   This cross-sectional, retrospective cohort study compared clinical information between two groups: PLHIV with subclinical atherosclerosis and PLHIV with IMT within the normal range. Due to the increased risk for CVD, carotid IMT measurement was performed as part of a routine clinical treatment plan for PLHIV at a 730-bed teaching hospital in Seoul, Korea. Among them, PLHIV who underwent carotid IMT measurement between January 2017 and January 2020 were included in the retrospective analysis. All of the individuals included in our study were over 18 years of age.

2. **Ethics statement**
   The study protocol was approved by the institutional review board (IRB) of Soonchunhyang University Seoul Hospital (IRB No. 2019-11-033). The need for patient consent was waived due to the retrospective nature of the study, and the risk posed to the participants was considered negligible compared to the potential public health benefits it may provide.

3. **Data collection**
   We collected data on demographic characteristics such as age, sex, smoking history, and body mass index (BMI), as well as each individual’s history of underlying diseases and opportunistic infections. The duration of HIV infection was calculated in months. We also collected laboratory findings including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), glucose, creatinine, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Dyslipidemia was defined as having levels of total cholesterol ≥240 mg/dL, LDL cholesterol ≥160 mg/dL, or HDL cholesterol <40 mg/dL in blood samples; or those receiving lipid-lowering therapy. We recorded the nadir CD4+ T cell count of each individual, along with the CD4+ T cell count and HIV RNA level checked closest to the time of
IMT measurement (within 3 months). Individuals were considered to have AIDS if they had a CD4+ T cell count <200 cells/mm³ or any one of the AIDS-defining conditions [16] at any time before data collection. We recorded the current ART regimen at the time of IMT measurement, and specified the medications into groups based on 3 core agents: integrase inhibitors (INI), protease inhibitors (PI), and non-nucleoside reverse transcriptase inhibitors (NNRTI).

4. Intima-media thickness measurement
IMT measurement was performed as part of the recommended evaluation for all PLHIV attending the hospital’s HIV/AIDS clinic. IMT was defined as the distance between the media-adventitia interface and the intima-lumen interface using the longitudinal view by ultrasound. Trained cardiologists measured IMT at a plaque-free area of the distal common carotid artery using automated software and a high-resolution B-mode ultrasound (EPIQ 5C or IE 33 ultrasound systems, Philips, Andover, MA, USA) equipped with an 11.0 MHz linear array transducer. The cardiologists measured both the right and left carotid IMTs, and selected the larger value. The normal range of IMT was defined as <0.8 mm, and values ≥0.8 mm were considered as increased IMT. Subclinical atherosclerosis was defined as either increased IMT or the presence of abnormal plaques in the carotid artery.

5. Statistical analysis
The Welch’s t-test or Mann-Whitney test was used to compare continuous variables, while the Chi-square test or Fisher’s exact test was used for categorical variables, as appropriate. A multivariable logistic regression model was designed using the variables that were different between the two groups (age, dyslipidemia, hypertension, total cholesterol, ESR, and HIV duration). In order to determine the cut-off value for predicting subclinical atherosclerosis, we calculated receiver operating characteristic (ROC) curves for age and HIV infection duration. Subsequently, we designed another binary logistic regression model as a subgroup analysis based on the age of 40 years. All tests were two-sided, and a P-value <0.05 was considered significant. All statistical analyses were performed using SPSS version 25.0 (IBM Corp, Armonk, NY, USA).

RESULTS
A total of 298 PLHIV visited the clinic during the study period. Seventy-three patients who did not undergo carotid IMT measurement were excluded, as well as 8 who were previously diagnosed with CVD. Thus, we included a total of 217 individuals in the final analysis. Among them, 211 (97.2%) were male, and the mean age was 40.5 ± 10.8 years. The median HIV infection duration was 67.7 months (interquartile range [IQR]: 38.2 - 101.2 months), and 91 participants (41.9%) experienced AIDS. IMT screening detected 115 patients (53.0%) with subclinical atherosclerosis.

The clinical characteristics of the subclinical atherosclerosis group and the control group are compared in Table 1. The mean age was significantly higher in the subclinical atherosclerosis group (45.4 vs. 35.1 years, P <0.001), and 32.2% had hypertension, compared to 19.6% in the control group (P = 0.04). The proportion of individuals with dyslipidemia was also significantly higher in the subclinical atherosclerosis group (55.7% vs. 16.7%, P <0.001), as well as the proportion of patients who were on lipid-lowering agents at the time of IMT measurement (21.7% vs. 9.8%, P = 0.02). There were no significant differences in the proportion of PLHIV with diabetes mellitus, osteoporosis, or chronic hepatitis B or C between the two groups. The median duration of HIV infection was 74.3 months (IQR: 41.1 - 118.1 months) in the subclinical atherosclerosis group, as compared to the control group, which had a median duration of 57.1
months (IQR: 33.9 - 88.6 months; \( P = 0.04 \)). There were no significant differences in the nadir and most recent CD4\(^+\) T cell counts between the two groups.

Total cholesterol was found to be higher in the subclinical atherosclerosis group (190.2 ± 37.1 vs. 180.0 ± 37.6 mg/dL, \( P = 0.047 \)). ESR was also significantly higher in the subclinical atherosclerosis group (24.4 ± 21.6 vs. 17.2 ± 16.8 mm/h, \( P = 0.007 \)), although there was no significant difference in CRP levels between the two groups. The antiretroviral medications used in both groups were similar, regardless of whether the patients were administered INIs, PIs, or NNRTIs.

Age and dyslipidemia were found to be significant in the univariable logistic regression analysis (odds ratio [OR]: for age 1.13, 95% confidence interval [CI]: 1.09 - 1.17, \( P < 0.001 \); OR for dyslipidemia 6.28, 95% CI: 3.32 - 11.87, \( P < 0.001 \), respectively), and we thus designed a multivariable logistic regression model using the variables that were significantly different between the two groups. In the multivariable logistic regression model, age and dyslipidemia were still associated with subclinical atherosclerosis (Table 2). ROC curves for age and HIV infection duration were plotted in order to determine the cut-off value of age for predicting subclinical atherosclerosis (Fig. 1). The cut-off value for age was 39.5 years, with the area under the curve (AUC) calculated to be 0.78 (95% CI: 0.72 - 0.84, \( P < 0.001 \)).

### Table 1. Clinical characteristics and laboratory findings of people living with HIV according to carotid IMT levels

|                      | Total (n = 217) | Subclinical atherosclerosis (n = 115) | Normal IMT (n = 102) | \( P \)-value |
|----------------------|----------------|--------------------------------------|----------------------|-------------|
| **Age (years)**      | 40.5 ± 10.8    | 45.4 ± 10.9                          | 35.1 ± 7.7           | <0.001      |
| **Male**             | 211 (97.2)     | 110 (95.7)                           | 101 (99.0)           | 0.22        |
| **BMI (kg/m\(^2\))**| 23.8 ± 3.2     | 24.1 ± 3.3                           | 23.6 ± 3.2           | 0.30        |
| **Smoking history**  | 125 (57.6)     | 66 (57.4)                            | 59 (57.8)            | 0.95        |
| **Underlying diseases** |              |                                      |                      |             |
| Hypertension         | 57 (26.3)      | 37 (32.2)                            | 20 (19.6)            | 0.04        |
| Diabetes mellitus    | 14 (6.5)       | 10 (8.7)                             | 4 (3.9)              | 0.18        |
| Dyslipidemia         | 81 (37.3)      | 64 (55.7)                            | 17 (16.7)            | <0.001      |
| Lipid-lowering agent use | 35 (16.1)  | 25 (21.7)                            | 10 (9.8)             | 0.02        |
| Osteopenia or osteoporosis | 102 (47.0)| 55 (47.8)                            | 47 (46.1)            | 0.80        |
| Chronic hepatitis B or C | 10 (4.6)   | 8 (7.0)                              | 2 (2.0)              | 0.11        |
| **HIV infection duration (months)** | 67.7 (38.2 - 101.2) | 74.3 (41.1 - 118.1) | 57.1 (33.9 - 88.6) | 0.04        |
| **CD4\(^+\) T cell count (cells/mm\(^3\))** | 255.0 (145.0 - 361.0) | 220.0 (129.0 - 361.5) | 260.0 (777.5 - 358.0) | 0.63        |
| **AIDS diagnosis**   | 91 (41.9)      | 55 (47.8)                            | 36 (35.3)            | 0.06        |
| **HIV RNA <200 copies/mL** | 199 (91.7) | 104 (90.4)                           | 95 (93.1)            | 0.47        |
| **Laboratory findings** |            |                                      |                      |             |
| Total cholesterol (mg/dL) | 185.4 ± 37.7  | 190.2 ± 37.1                         | 180.0 ± 37.6         | 0.047       |
| LDL (mg/dL)          | 118.3 ± 35.5   | 122.1 ± 37.0                         | 114.0 ± 33.1         | 0.10        |
| HDL (mg/dL)          | 50.7 ± 12.4    | 49.5 ± 13.7                          | 52.1 ± 10.7          | 0.11        |
| Glucose (mg/dL)      | 109.0 ± 39.7   | 111.2 ± 32.7                         | 106.5 ± 45.7         | 0.39        |
| Creatinine (mg/dL)   | 1.0 ± 0.2      | 1.0 ± 0.2                            | 1.0 ± 0.1            | 0.64        |
| C-reactive protein (mg/dL) | 0.1 (0.0 - 0.2)   | 0.1 (0.0 - 0.2)                   | 0.1 (0.0 - 0.1)      | 0.94        |
| ESR (mm/h)           | 21.0 ± 19.8    | 24.4 ± 21.6                          | 17.2 ± 16.8          | 0.007       |
| **Medication**       |                |                                      |                      |             |
| INI                   | 193 (88.9)     | 102 (88.7)                           | 91 (89.2)            | 0.90        |
| PI                    | 24 (11.1)      | 13 (11.3)                            | 11 (10.8)            | 0.90        |
| NNRTI                 | 11 (5.1)       | 5 (4.3)                              | 6 (5.0)              | 0.76        |

Data are expressed as mean ± standard deviation, median (interquartile range), or number (%).

HIV, human immunodeficiency virus; IMT, intima-media thickness; BMI, body mass index; AIDS, acquired immunodeficiency syndrome; RNA, ribonucleic acid; LDL, low density lipoprotein; HDL, high density lipoprotein; ESR, erythrocyte sedimentation rate; INI, integrase inhibitors; PI, protease inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors.
In the subgroup analysis of risk factors for subclinical atherosclerosis based on the age of 40 years, dyslipidemia was still significantly associated with subclinical atherosclerosis in both groups, but the association was stronger in the group aged <40 years than in the group aged ≥40 years (OR: 9.73, 95% CI: 3.03 - 31.27, \( P < 0.001 \); OR: 3.35, 95% CI: 1.22 - 9.22, \( P = 0.02 \), respectively; Table 3).

**DISCUSSION**

Age is an important risk factor in CVD, but the exact cut-off age remains unclear. In previous studies, study populations were either in their 40s or older, or 50s or older [10, 17]. In the 2019 update on the management of CVD in PLHIV, screening is recommended for those who are

| Table 3. Subgroup analysis of risk factors for subclinical atherosclerosis based on age 40 |
|-----------------------------------------------|-----------------------------------------------|
| **Age <40 years (n = 109)** | **Age ≥40 years (n = 108)** |
| **Odds ratio** | **95% confidence interval** | **P-value** | **Odds ratio** | **95% confidence interval** | **P-value** |
| Dyslipidemia | 9.73 | 3.03 - 31.27 | <0.001 | 3.35 | 1.22 - 9.22 | 0.02 |
| Hypertension | 2.69 | 0.88 - 8.29 | 0.08 | 0.48 | 0.16 - 1.41 | 0.18 |
| HIV infection duration | 1.01 | 1.00 - 1.02 | 0.24 | 1.00 | 0.99 - 1.01 | 0.92 |
| ESR | 1.01 | 1.00 - 1.03 | 0.32 | 1.02 | 0.99 - 1.05 | 0.13 |
| Total cholesterol | 1.01 | 0.99 - 1.02 | 0.26 | 1.00 | 0.99 - 1.01 | 0.85 |

HIV, human immunodeficiency virus; ESR, erythrocyte sedimentation rate.
over 40 and at risk for developing CVD [18]. However, our study showed that age ≥40 years was independently associated with atherosclerosis. Atherosclerosis is often diagnosed belatedly with the occurrence of an irreversible major cardiovascular event because of its asymptomatic nature during the early phase. Early diagnosis and statin therapy are associated with significant changes in the rate of disease progression, and thus may reduce the risk of acute cardiovascular events [19]. Therefore, even if there are no other risk factors, it is advisable to monitor the development of atherosclerosis in PLHIV over 40 years of age. Our subgroup analysis showed that the association between dyslipidemia and subclinical atherosclerosis was weakened in patients over the age of 40. In addition to the results of the ROC curve analysis, these findings indicate that age, which is an easily obtained indicator in the clinical setting, can be used to predict subclinical atherosclerosis and recommend screening in Asian PLHIV.

The results from our study showed the cut-off age for predicting subclinical atherosclerosis to be 39.5 years. This may be supporting evidence for routine carotid IMT screening of PLHIV over this age. This is approximately 5 years earlier than the guidelines on noninvasive screening of subclinical atherosclerosis in the general population (45 - 75 years in men, and 55 - 75 years in women) [9]. Initiating statin therapy based on high-risk subclinical atherosclerosis results in a relative risk reduction of 35.0%, and thus, an average of 0.58 years of life are saved compared to patients screened using only traditional risk factors such as the Framingham Risk Score [9].

The prevalence of subclinical atherosclerosis in PLHIV included in this study was higher than the prevalence of carotid atherosclerosis in the general population, which is approximately 25.4% in men and 26.4% in women [20]. Since a higher prevalence was found in Asians, in whom atherosclerosis is less noticeable than in other races [15], these results may be applicable in other races as well.

While there is scant knowledge on HIV-associated atherosclerosis in Korea, one previous study described the clinical factors associated with atherosclerosis among 145 PLHIV in Korea [21]. In their cohort, 23.4% of the participants had carotid plaques, while our study showed approximately 53.0% to have subclinical atherosclerosis. In addition to the difference in the definitions of abnormal IMT, the gap in the prevalence of abnormal IMT is likely due to the relatively longer HIV infection duration (67.7 vs. 53.0 months) or the higher total cholesterol levels of the patients in our study.

While the proportion of PLHIV with AIDS was not significantly different between the two groups, further analysis showed that PLHIV with AIDS were older (44.4 vs. 37.8 years, \( P < 0.001 \)), and had a longer HIV duration (84.6 vs. 67.0 months, \( P = 0.008 \)) than those without. This is likely associated with the fact that since 2013, PLHIV in Korea have been treated with ART regardless of their CD4+ T cell counts.

This study has limitations stemming from its retrospective nature. First, we could not compare the results based on sex, because most of our subjects were men. This result is consistent with the fact that approximately 90.9% of PLHIV in Korea are men [22]. However, monitoring for atherosclerosis in women is still necessary because more than 30% of female PLHIV in Korea are over 50 years old [23], and conventional risk factors alone are reported to be insufficient to detect atherosclerosis in women [24]. Second, this study could not reflect further changes in treatment over time. Certain ART medications, such as some PIs or abacavir, are reported to be associated with premature carotid lesions [25-27]. This study did not show any significant association regardless of the ART category. There could
be a bias since physicians tend to avoid medications with potential cardiovascular risks in patients with conventional risk factors. Also, the size of the study population may have been insufficient to show a meaningful comparison regarding this issue.

In conclusion, this study suggests that older age and dyslipidemia are significantly associated with subclinical atherosclerosis in PLHIV. PLHIV over 39.5 years of age have an increased risk of subclinical atherosclerosis and may benefit from carotid IMT screening regardless of conventional risk factors. Since dyslipidemia is strongly associated with subclinical atherosclerosis in PLHIV aged <40 years, carotid IMT screening might also be considered in younger PLHIV with dyslipidemia.

REFERENCES

1. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23:1059-67.
PUBMED | CROSSREF

2. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Snieja M; Working Group 2. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35.
PUBMED | CROSSREF

3. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011;62:141-55.
PUBMED | CROSSREF

4. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, Ubolyam S, Carr A, Luxungham K, Hirschel B, Anawarich J; STACCATO Study Group. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009;23:929-39.
PUBMED | CROSSREF

5. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012;13:453-68.
PUBMED | CROSSREF

6. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-8.
PUBMED | CROSSREF

7. Lichtenstein KA, Aronson C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, Wood K, Holmberg SD, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010;51:435-47.
PUBMED | CROSSREF

8. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS; American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111; quiz 189-90.
PUBMED | CROSSREF

9. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK; SHAPE Task Force. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) task force report. Am J Cardiol 2006;98 2A:2H-15H.
PUBMED | CROSSREF

10. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, Tien PC, Shlipak MG, Sidney S, Polak JF, O’Leary D, Bacchetti P, Komnall RA. Preclinical atherosclerosis due to HIV infection: carotid intima-media thickness measurements from the FRAM study. AIDS 2009;23:1841-9.
PUBMED | CROSSREF

11. Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol 2012;109:742-7.
PUBMED | CROSSREF
12. Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, Meneghetti G, Tinelli C, Testa S. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162:433-8.
PUBMED | CROSSREF

13. Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, Lees RS, Lee H, Grinspoon S. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4916-24.
PUBMED | CROSSREF

14. Bijker R, Jiamsakul A, Uy E, Kumarasamy N, Dikango R, Chaiwarith R, Wong WW, Avihingsanon A, Sun LP, Yunihastuti E, Pujari S, Do CD, Merati TP, Kantipong P, Nguyen KV, Kamarulzaman A, Zhang F, Lee MP, Choi JY, Tanuma J, Ng OT, Sim B, Ross J, Kiertiburanakul S; TREAT Asia HIV Observational Database (TAHOD) of iDEA Asia-Pacific. Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2019;20:183-91.
PUBMED | CROSSREF

15. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E, Ouyang P, Jackson S, Saad MF. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005;111:1313-20.
PUBMED | CROSSREF

16. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT; Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. MMWR Recomm Rep 2008;57 RR-10:1-12.
PUBMED

17. Mangili A, Polak JF, Skinner SC, Gerrior J, Sheehan H, Harrington A, Wanke CA. HIV infection and progression of carotid and coronary atherosclerosis: the CARE study. J Acquir Immune Defic Syndr 2011;58:148-53.
PUBMED | CROSSREF

18. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberger MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association. Circulation 2019;140:e98-e124.
PUBMED | CROSSREF

19. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract 2008;62:1246-54.
PUBMED | CROSSREF

20. Prati P, Vanuzzo D, Casaroli M, Di Chiara A, De Biasi F, Feruglio GA, Touboul PJ. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke 1992;23:1705-11.
PUBMED | CROSSREF

21. Jeong SJ, Kim HW, Ku NS, Han SH, Kim CO, Choi JY, Song YG, Kim JM. Clinical factors associated with carotid plaque and intima-medial thickness in HIV-infected patients. Yonsei Med J 2013;54:990-8.
PUBMED | CROSSREF

22. Jung Y, Cha J, Kim T, Shim EH. HIV/AIDS notifications in Korea, 2019. Pub Health Weekly Rep 2020;13:2574-9.
PUBMED

23. Lee E, Kim J, Bang JH, Lee JY. Suboptimal medication adherence in young women living with HIV infection: a Korean nationwide claims study. AIDS Care 2021;33:938-42.
PUBMED | CROSSREF

24. Michos ED, Nasir K, Braunstein JB, Rumberger JA, Budoff MJ, Post WS, Blumenthal RS. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006;184:201-6.
PUBMED | CROSSREF

25. Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A; PREVALEAT Group. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004;18:i1023-8.
PUBMED | CROSSREF

26. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G, Pastore G. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2006;20:F123-8.
PUBMED | CROSSREF

27. Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Duhe MP, Murphy RL, Currier JS. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015;29:1775-83.
PUBMED | CROSSREF